Update on alpha-1 antitrypsin deficiency: New therapies

Journal of Hepatology

Volumn 65, Issue 2, 2016, Pages 413-424

  Lomas, David A ^a,b,c   Hurst, John R ^a,b   Gooptu, Bibek ^b,c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

Cirrhosis; Emphysema; Polymerisation; Serpins; Therapeutic strategies

Indexed keywords

ALPHA 1 ANTITRYPSIN; RETINOIC ACID;

ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOPHAGY; BEHAVIOR MODIFICATION; CELL INCLUSION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; HUMAN; INFLAMMATION; INTRACELLULAR SPACE; LIVER CIRRHOSIS; LIVER DISEASE; LUNG EMPHYSEMA; LUNG TRANSPLANTATION; MOLECULAR PATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN POLYMERIZATION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SERPINOPATHY; STEM CELL TRANSPLANTATION; SUBSTITUTION THERAPY; ANIMAL;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; HUMANS;

EID: 84973885468     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.03.010     Document Type: Review

References (98)

1. [1] Lomas, D.A., Mahadeva, R., Alpha-1-antitrypsin polymerisation and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 110 (2002), 1585–1590.
2. 1-antitrypsin accumulation in the liver. Nature 357 (1992), 605–607.
3. 1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 294 (1976), 1316–1321.
4. 1-antitrypsin deficiency. N Engl J Med 314 (1986), 736–739.
5. [5] Dawwas, M.F., Davies, S.E., Griffiths, W.J., Lomas, D.A., Alexander, G.J., Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am J Respir Crit Care Med 187 (2013), 502–508.
6. [6] Eriksson, S., Studies in α1-antitrypsin deficiency. Acta Med Scand 432 (1965), 1–85.
7. 1-antitrypsin deficiency. Hepatology 52 (2010), 1078–1088.
8. 1-antitrypsin. J Biol Chem 274 (1999), 9548–9555.
9. 1-antichymotrypsin indicates two stage insertion of the reactive loop; implications for inhibitory function and conformational disease. Proc Natl Acad Sci U S A 97 (2000), 67–72.
10. [10] Haq, I., Irving, J.A., Faull, S.V., Dickens, J.A., Ordóñez, A., Belorgey, D., et al. Reactive centre loop mutants of α-1-antitrypsin reveal position-specific effects on intermediate formation along the polymerization pathway. Biosci Rep, 33, 2013, e00046.
11. [11] Irving, J.A., Haq, I., Dickens, J.A., Faull, S.V., Lomas, D.A., Altered native stability is the dominant basis for susceptibility of α1-antitrypsin mutants to polymerization. Biochem J 460 (2014), 103–115.
12. [12] Haq, I., Irving, J.A., Saleh, A.D., Dron, L., Regan-Mochrie, G.L., Motamedi-Shad, N., et al. Deficiency mutations of alpha-1 antitrypsin. Effects on folding, function, and polymerization. Am J Respir Cell Mol Biol 54 (2016), 71–80.
13. [13] Gooptu, B., Miranda, E., Nobeli, I., Mallya, M., Purkiss, A., Leigh Brown, S.C., et al. Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha-1-antitrypsin: implications for disease and drug design. J Mol Biol 387 (2009), 857–868.
14. [14] Nyon, M.P., Segu, L., Cabrita, L.D., Lévy, G.R., Kirkpatrick, J., Roussel, B.D., et al. Structural dynamics associated with intermediate formation in an archetypal conformational disease. Structure 20 (2012), 504–512.
15. [15] Ekeowa, U.I., Freekeb, J., Miranda, E., Gooptu, B., Bush, M.F., Pérez, J., et al. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci U S A 107 (2010), 17146–17151.
16. [16] Nyon, M.P., Prentice, T., Day, J., Kirkpatrick, J., Sivalingam, G.N., Levy, G., et al. An integrative approach combining ion mobility mass spectrometry, X-ray crystallography and NMR spectroscopy to study the conformational dynamics of α1-antitrypsin upon ligand binding. Protein Sci 24 (2015), 1301–1312.
17. 53 –>Phe); further evidence for intracellular loop-sheet polymerisation. J Biol Chem 268 (1993), 15333–15335.
18. 52Phe deleted) forms loop-sheet polymers in vivo: evidence for the C sheet mechanism of polymerisation. J Biol Chem 270 (1995), 16864–16870.
19. 1-antitrypsin. Nat Struct Biol 3 (1996), 910–911.
20. 1-antitrypsin and liver cirrhosis. J Clin Invest 103 (1999), 999–1006.
21. 1-antitrypsin promotes aggregation. J Mol Biol 396 (2010), 375–383.
22. [22] Nyon, M.P., Gooptu, B., Therapeutic targeting of misfolding and conformational change in α1-antitrypsin deficiency. Future Med Chem 6 (2014), 1047–1065.
23. [23] Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Cao, D., Neuberger, T., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106 (2009), 18825–18830.
24. [24] Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Stack, J.H., Straley, K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 108 (2011), 18843–18848.
25. [25] Yamasaki, M., Li, W., Johnson, D.J., Huntington, J.A., Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455 (2008), 1255–1258.
26. [26] Krishnan, B., Gierasch, L.M., Dynamic local unfolding in the serpin α-1 antitrypsin provides a mechanism for loop insertion and polymerization. Nat Struct Mol Biol 18 (2011), 222–226.
27. [27] Tsutsui, Y., Dela Cruz, R., Wintrode, P.L., Folding mechanism of the metastable serpin α1-antitrypsin. Proc Natl Acad Sci U S A 109 (2012), 4467–4472.
28. [28] Yamasaki, M., Sendall, T.J., Pearce, M.C., Whisstock, J.C., Huntington, J.A., Molecular basis of α1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep 12 (2011), 1011–1017.
29. [29] Behrens, M.A., Sendall, T.J., Pedersen, J.S., Kjeldgaard, M., Huntington, J.A., Jensen, J.K., The shapes of Z-α1-antitrypsin polymers in solution support the C-terminal domain-swap mechanism of polymerization. Biophysical J 107 (2014), 1905–1912.
30. [30] Kröger, H., Miranda, E., MacLeod, I., Pérez, J., Crowther, D.C., Marciniak, S.J., et al. Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. J Biol Chem 284 (2009), 22793–22802.
31. 1-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol 279 (2000), G961–G974.
32. 1-antitrypsin deficiency. J Biol Chem 282 (2007), 27769–27780.
33. [33] Ordóñez, A., Snapp, E.L., Tan, L., Miranda, E., Marciniak, S.J., Lomas, D.A., Endoplasmic reticulum polymers impair luminal protein mobility and sensitize to cellular stress in alpha-1-antitrypsin deficiency. Hepatology 57 (2013), 2049–2060.
34. 1-antitrypsin deficiency. J Immunol 172 (2004), 5722–5726.
35. [35] Davies, M.J., Miranda, E., Roussel, B.D., Kaufman, R.J., Marciniak, S.J., Lomas, D.A., Neuroserpin polymers activate NF-kB by a calcium signalling pathway that is independent of the unfolded protein response. J Biol Chem 284 (2009), 18202–18209.
36. [36] Fregonese, L., Stolk, J., Frants, R.R., Veldhuisen, B., Alpha-1 antitrypsin Null mutations and severity of emphysema. Respir Med 102 (2008), 876–884.
37. 1-antitrypsin deficiency. Am J Respir Crit Care Med 154 (1996), 1718–1725.
38. [38] Seersholm, N., Kok-Jensen, A., Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema?. Respir Med 92 (1998), 241–245.
39. 1-antitrypsin related emphysema. Am J Respir Cell Mol Biol 18 (1998), 670–674.
40. 1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 125 (2004), 1952–1957.
41. [41] van't Wout, E.F., Dickens, J.A., van Schadewijk, A., Haq, I., Kwok, H.F., Ordóñez, A, et al. Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α1-antitrypsin. Hum Mol Genet 23 (2014), 929–941.
42. 1-antitrypsin co-localise with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 166 (2005), 377–386.
43. [43] Alam, S., Li, Z., Janciauskiene, S., Mahadeva, R., Oxidation of Z alpha-1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol 45 (2011), 261–269.
44. 1-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 26 (2002), 723–730.
45. [45] Tan, L., Dickens, J.A., Demeo, D.L., Miranda, E., Perez, J., Rashid, S.T., et al. Circulating polymers in α1-antitrypsin deficiency. Eur Respir J 43 (2014), 1501–1504.
46. [46] Gooptu, B., Lomas, D.A., Conformational pathology of the serpins - themes, variations and therapeutic strategies. Annu Rev Biochem 78 (2009), 147–176.
47. [47] Davis, R.L., Shrimpton, A.E., Holohan, P.D., Bradshaw, C., Feiglin, D., Sonderegger, P., et al. Familial dementia caused by polymerisation of mutant neuroserpin. Nature 401 (1999), 376–379.
48. [48] Davis, R.L., Shrimpton, A.E., Carrell, R.W., Lomas, D.A., Gerhard, L., Baumann, B., et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 359 (2002), 2242–2247.
49. [49] Coutelier, M., Andries, S., Ghariani, S., Dan, B., Duyckaerts, C., van Rijckevorsel, K., et al. Neuroserpin mutation causes electrical status epilepticus of slow-wave sleep. Neurology 71 (2008), 64–66.
50. [50] Hagen, M., Murrell, J.R., Delisle, M.B., Andermann, E., Andermann, F., Guiot, M.C., et al. Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the proteinase inhibitor 12 Gene. Brain Pathol 21 (2011), 575–582.
51. [51] Belorgey, D., Crowther, D.C., Mahadeva, R., Lomas, D.A., Mutant neuroserpin (Ser49Pro) that causes the familial dementia FENIB is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 277 (2002), 17367–17373.
52. [52] Miranda, E., Römisch, K., Lomas, D.A., Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem 279 (2004), 28283–28291.
53. [53] Belorgey, D., Sharp, L.K., Crowther, D.C., Onda, M., Johansson, J., Lomas, D.A., Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur J Biochem 271 (2004), 3360–3367.
54. [54] Miranda, E., McLeod, I., Davies, M.J., Pérez, J., Römisch, K., Crowther, D.C., et al. The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet 17 (2008), 1527–1539.
55. [55] Takehara, S., Onda, M., Zhang, J., Nishiyama, M., Yang, X., Mikami, B., et al. The 2.1-A crystal structure of native neuroserpin reveals unique structural elements that contribute to conformational instability. J Mol Biol 388 (2009), 11–20.
56. [56] Belorgey, D., Hägglöf, P., Onda, M., Lomas, D.A., PH dependent stability of neuroserpin is mediated by Histidines 119 and 138; implications for the control of β-sheet A and polymerisation. Protein Sci 19 (2010), 220–228.
57. [57] Schipanski, A., Lange, S., Segref, A., Gutschmidt, A., Lomas, D.A., Miranda, E., et al. A novel interaction between aging and ER overload in a protein conformational dementia. Genetics 193 (2013), 865–876.
58. [58] Gooptu, B., Lomas, D.A., Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med 205 (2008), 1529–1534.
59. 1-antitrypsin deficiency. Trends Mol Med 20 (2014), 116–127.
60. 1-antitrypsin deficiency. Am J Respir Crit Care Med 162 (2000), 553–558.
61. [61] Stoller, J.K., Aboussouan, L.S., Alpha-1 antitrypsin deficiency. Lancet 365 (2005), 2225–2236.
62. 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160 (1999), 1468–1472.
63. [63] Dirksen, A., Piitulainen, E., Parr, D.G., Deng, C., Wencker, M., Shaker, S.B., et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 33 (2009), 1345–1353.
64. [64] Dickens, J.A., Lomas, D.A., Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther 5 (2011), 391–405.
65. [65] Lange, P., Celli, B., Agustí, A., Boje Jensen, G., Divo, M., Faner, R., et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 373 (2015), 111–122.
66. [66] Chapman, K.R., Burdon, J.G., Piitulainen, E., Sandhaus, R.A., Seersholm, N., Stocks, J.M., et al. Intravenous augmentation treatment and lung density in severe α1-antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 386 (2015), 360–368.
67. [67] Jedicke, N., Struever, N., Aggrawal, N., Welte, T., Manns, M.P., Malek, N.P., et al. α-1-antitrypsin inhibits acute liver failure in mice. Hepatology 59 (2014), 2299–2308.
68. [68] Mueller, C., Flotte, T.R., Gene-based therapy for alpha-1 antitrypsin deficiency. COPD 10 (2013), 44–49.
69. [69] Massaro, G.D., Massaro, D., Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 3 (1997), 675–677.
70. [70] Stolk, J., Stockley, R.A., Stoel, B.C., Cooper, B.G., Piitulainen, E., Seersholm, N., et al. Randomized controlled trial for emphysema with a selective agonist of the gamma type retinoic acid receptor. Eur Respir J 40 (2012), 306–312.
71. [71] Donahue, J.M., Cassivi, S.D., Lung volume reduction surgery for patients with alpha-1 antitrypsin deficiency emphysema. Thorac Surg Clin 19 (2009), 201–208.
72. [72] Hillerdal, G., Mindus, S., One- to four-year follow-up of endobronchial lung volume reduction in alpha-1-antitrypsin deficiency patients: a case series. Respiration 88 (2014), 320–328.
73. 1-AT deficiency. Am J Respir Cell Mol Biol 24 (2001), 727–732.
74. 1-AT) Z: a potential pharmacologcial strategy for prevention of liver injury and emphysema. Proc Natl Acad Sci U S A 97 (2000), 1796–1801.
75. [75] Teckman, J.H., Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr 39 (2004), 34–37.
76. [76] Hidvegi, T., Ewing, M., Hale, P., Dippold, C., Beckett, C., Kemp, C., et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 329 (2010), 229–232.
77. [77] Kaushal, S., Annamali, M., Blomenkamp, K., Rudnick, D., Halloran, D., Brunt, E.M., et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood) 235 (2010), 700–709.
78. [78] Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B.A., et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403 (2000), 98–103.
79. [79] Pastore, N., Ballabio, A., Brunetti-Pierri, N., Autophagy master regulator TFEB induces clearance of toxic SERPINA1/α-1-antitrypsin polymers. Autophagy 9 (2013), 1094–1096.
80. [80] Bouchecareilh, M., Hutta, D.M., Szajnera, P., Flotte, T.R., Balch, W.E., Histone Deacetylase inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA) mediated correction of alpha-1 antitrypsin deficiency. J Biol Chem 287 (2012), 38265–38278.
81. [81] Wooddell, C.I., Blomenkamp, K.S., Kanner, S., Chu, Q., Hamilton, H.L., Wakefield, D.H., et al. A hepatocyte-targeted RNAi-based treatment for liver disease associated with alpha-1-antitrypsin deficiency. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 7–11; 2014, 2014 Boston, Massachusetts.
82. [82] Sehgal, A., Blomenkamp, K.S., Qian, K., Simon, A., Haslett, P., Barros, S., et al. Pre-clinical evaluation of ALN-AAT to ameliorate liver disease associated with alpha-1-antitrypsin deficiency. Gastroenterology, 148, 2015, S-975.
83. [83] Guo, S., Booten, S.L., Aghajan, M., Hung, G., Zhao, C., Blomenkamp, K., et al. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest 124 (2014), 251–261.
84. 1-antitrypsin. Biochemistry 32 (1993), 500–508.
85. [85] Skinner, R., Chang, W.-S.W., Jin, L., Pei, X., Huntington, J.A., Abrahams, J.-P., et al. Implications for function and therapy of a 2.9Å structure of binary-complexed antithrombin. J Mol Biol 283 (1998), 9–14.
86. 1-antitrypsin related cirrhosis. J Biol Chem 277 (2002), 6771–6774.
87. 1-antitrypsin related emphysema. Am J Respir Cell Mol Biol 31 (2004), 133–139.
88. [88] Zhou, A., Stein, P.E., Huntington, J.A., Sivasothy, P., Lomas, D.A., Carrell, R.W., How small peptides block and reverse serpin polymerization. J Mol Biol 342 (2004), 931–941.
89. [89] Elliott, P.R., Pei, X.Y., Dafforn, T.R., Lomas, D.A., Topography of a 2.0Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci 9 (2000), 1274–1281.
90. 1-antitrypsin to prevent conformational disease. J Biol Chem 278 (2003), 33060–33066.
91. 1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 50 (2007), 5357–5363.
92. [92] Tan, L., Perez, J., Mela, M., Miranda, E., Burling, K.A., Rouhani, F.N., et al. Characterising the association of latency with α1-antitrypsin polymerisation using a novel monoclonal antibody. Int J Biochem Cell Biol 58 (2015), 81–91.
93. [93] Irving, J.A., Miranda, E., Haq, I., Perez, J., Kotov, V.R., Faull, S.V., et al. An antibody raised against a pathogenic serpin variant induces mutant-like behaviour in the wild-type protein. Biochem J 468 (2015), 99–108.
94. [94] Ordóñez, A., Pérez, J., Tan, L., Dickens, J.A., Motamedi-Shad, N., Irving, J.A., et al. A single-chain variable fragment intrabody prevents intracellular polymerisation of Z α1-antitrypsin. FASEB J 29 (2015), 2667–2678.
95. [95] Rashid, S.T., Corbineau, S., Hannan, N., Marciniak, S.J., Miranda, E., Alexander, G., et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 120 (2010), 3127–3136.
96. [96] Wilson, A.A., Yin, L., Liesa, M., Segeritz, C.P., Mills, J.A., Shen, S.S., et al. Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells. Stem Cell Rep 4 (2015), 873–885.
97. [97] Yusa, K., Rashid, S.T., Strick-Marchand, H., Varela, I., Liu, P.Q., Paschon, D.E., et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478 (2011), 391–394.
98. [98] Patschull, A.O., Gooptu, B., Ashford, P., Daviter, T., Nobeli, I., In silico assessment of potential druggable pockets on the surface of α1-antitrypsin conformers. PLoS One, 7, 2012, e36612.